Tildrakizumab was shown to be efficacious in treating moderate-to-severe plaque psoriasis on the scalp.

Topical treatment decreases itch and improves sleep patterns in patients with psoriasis and atopic dermatitis.

The visibility of a skin disorder is directly linked to stigma including bullying.

Topical melatonin and topical rosuvastatin were both effective in reducing the severity of mild-to-moderate plaque PsO.

Guselkumab is efficacious in patients with moderate-to-severe psoriasis and a history of cancer.

Apremilast is effective for the treatment of moderate-to-severe plaque psoriasis short-term in pediatric patients.

Plaque psoriasis patients with lower blood monocyte counts at baseline achieved early response when treated with secukinumab.

Guselkumab has shown improvements in skin clearance, scalp itch, and patient-report health-related QoL in skin of colour patients.